Arjun Oberoi, MD

Diaverum Singapore has officially signed the tender award agreement with Woodlands Health Campus, marking a pivotal milestone in its expansion. Once operational, it will bring Diaverum Singapore’s network of clinics to a total of 12, reaffirming our commitment to making life-enhancing treatment accessible in areas it is needed most. “This moment is the culmination of our team’s relentless hard work and persistence,” said Venanssa Goh, Country Manager of Diaverum Singapore. “Taking official possession of the site is not only a tremendous milestone for us, but also a powerful testament to the dedication and commitment our team has demonstrated throughout this journey. Now, the real excitement begins as we bring our vision to life.”    Amantur Ryskulov, General Manager for Central Asia and Southeast Asia, added:  “This partnership underscores Diaverum’s commitment to delivering world-class renal care and advancing healthcare excellence across the region. The Woodlands Health Campus project not only strengthens our presence in Singapore but also reflects our vision of creating sustainable, patient-focused renal care solutions that can serve as a benchmark for other markets we operate in.”  With the agreement in place, Diaverum Singapore will begin preparations to deliver outstanding care at the new site, reinforcing the company’s mission to improve the quality of life for patients in the community. Learn more: http://bit.ly/47JaEVr #Diaverum #M42 #TrueCare #LifeEnhancingRenalCare #RenalCareMarket #Growth

89

2 Comments

📢🔥 St Vincent's Hospital Melbourne (SVHM) and Mobius Medical are excited to announce our new Site Alliance Partnership to drive further efficiencies into clinical study start up and execution. 🏥🤝🏢 The Partnership agreement was signed at the 2025 BIO Asia–Taiwan on 25 July by the two organisations representative: ✍ Assoc Prof Tam C. Nguyen , Deputy Director of Research, SVHM ✍ Stefan Czyniewski, Clinical Research Director and Co-Founder, Mobius Medical 🌐🏢 Founded over 17 years ago, Mobius Medical is a founder-led, ISO 9001-certified CRO delivering high-performance clinical trials across Australia, New Zealand, and the United States. Mobius Medical delivers high quality clinical trials specialising in MedTech trials including medical device, IVD and drug device combination products. Mobius provides clinical strategic advice, scientific and regulatory rigor, and project execution from Early Feasibility Studies (EFS) to pivotal trails aimed at product commercialisation.   🏥⚕ St Vincent's Hospital Melbourne (SVHM) is part of St Vincent's Health Australia (SVHA) network, a $2 billion not-for-profit health and aged care provider. SVHA is the 12th largest private company in the country, and the second largest healthcare provider with more than 35 facilities spanning public, private and aged care. 🏥⚕SVHM is one of five tertiary teaching hospitals in Victoria with research programs including clinical trials (Phases I-IV) in drugs, devices, diagnostic, GMO/cell therapies and AI/Machine Learning studies. The signing was witnessed by colleagues, collaborators and representative from Australian Trade and Investment Commission (Austrade) at the Australian Pavillion. 📸Christopher Lim MAICD, Senior Trade and Investment Commissioner & Deputy Representative, Australian Office, Taipei Duli Chang, Senior Business Development Manager, Australian Trade and Investment Commission (Austrade) Sam Huang, BD Manager, Austrade 🤝💥This Alliance Partnership is in addition to St Vincent's existing site alliance partnerships with other major and boutique CROs including: IQVIA, Syneos Health, Parexel , PPD, Accelagen Pty Ltd., Fortrea and HiRO - Harvest Integrated Research Organization. 👍𝑳𝒊𝒌𝒆 ♻𝑹𝒆𝒑𝒐𝒔𝒕 💬 𝑪𝒐𝒎𝒎𝒆𝒏𝒕 &🔖𝑻𝒂𝒈 31.07.25 #clinicaltrials #clinicalresearch #medicalresearch #medtech #medicaldevices #lifesciences #healthcare #researchvalet #partnership

119

18 Comments

FINN Partners Global Health Practice Lead Fern Lazar kicks off a best-in-class conversation on the emerging world of venture capital with three top voices in Japan. Japan's venture landscape is quietly hitting a new stride. The nation's HealthTech sector, already the world's third-largest market for medical devices and pharma, is seeing venture investment growth that outpaces both Europe and North America—and has for the last five years. This is a unique exchange, looking inside the investment engine of one of the world's leading global health innovation hubs. Featuring: 🔹 Yukiko Kato, SBI Investment 🔹 Yumiko Murakami, MPower Partners 🔹 Nagisa Sakurai, PhD, MBA, Astellas Pharma - Astellas Venture Management #VC #investment #healthinnovation #healthtech #Japan Levi Shapiro 🎗

70

10 Comments